Antitumoral Phortress Small Molecule (Tool Compound)

The Antitumoral Phortress compound is a potential anticancer agent for treatment of human breast carcinoma. Phortress is highly selective for susceptible cancer cells because of its mechanism of action.

Contributors

Inventor Institute
Malcolm F G Stevens University of Nottingham
Cat. #: 151839
Tool sub type: Antitumoral
Research Fields: Cancer;Cell biology;Genetics
Application: Active against breast, ovarian and renal carcinomas. Taken up into sensitive cells followed by aryl hydrocarbon receptor binding and translocation into the nucleus. Requires metabolic activation by cytochrome P450 to generate cytotoxic species. Induces expression of CYP1A1 and generates adducts in the DNA of sensitive MCF7 and IGROV-1 cells.
Product description: The Antitumoral Phortress compound is a potential anticancer agent for treatment of human breast carcinoma. Phortress is highly selective for susceptible cancer cells because of its mechanism of action. Following the release of 5F 203 from Phortress, it activates AhR signalling and causes induction of cytochrome P450 activity, which metabolically bioactivates 5F 203 to a cytotoxic species at the tumour site.Phortress (the dihydrochloride salt of the lysylamide prodrug of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203)) is an experimental antitumour agent with potent and selective activity against human-derived carcinomas of breast, ovarian and renal originThe mechanism of action of Phortress is distinct from all classes of chemotherapeutic agents currently in the clinic, and involves metabolic activation by cytochrome P450 (CYP) 1A1 to electrophilic species, which generate DNA adducts in sensitive tumours only.
Additional notes: Compound available for screening or similar studies. For larger quantities (>20mg) please contact Ximbio. Product Documents: Phortress Diode Array Phortress NMR <a href="https://koi-3QNH6P8D7I.marketingautomati…
Molecular weight: 459.41
Primary target: Human derived carcinomas of breast, ovarian and renal origin
Shipping conditions: Dry Ice
References:

Bradshaw et al. 2009. Pharmacology. 83(2):99-109. PMID: 19088497.

Preclinical toxicokinetic evaluation of phortress [2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole lysylamide dihydrochloride] in two rodent species.

Fichtner et al. 2004. Breast Cancer Res Treat. 87(1):97-107. PMID: 15377855.

The experimental antitumor agents Phortress and doxorubicin are equiactive against human-derived breast carcinoma xenograft models.

Bradshaw et al. 2004. Curr Med Chem. 11(8):1009-21. PMID: 15078…

Images

View Gallery

Related Tools for Small molecules

Cat. # Tool Name
151711 MGMT inhibitor Lomeguatrib Small Molecule (Tool Compound) Key Info View Tool
152709 Dual DNA-PK/PI3K inhibitor KU-0060648 Small Molecule (Tool Compound) Key Info View Tool
152741 Platinum trimethyl Luminophore Small Molecule (Tool Compound) Key Info View Tool
152789 Glucose-6-phosphate Dehydrogenase inhibitor G6PD Small Molecule (Collaborative Toolkit) Key Info View Tool
153334 HDAC3:SMRT Fluorescent Probe 2-FAM-InsP5 Small Molecule (Tool Compound) Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.